[go: up one dir, main page]

PE20091187A1 - Compuestos derivados de quinolina como moduladores del receptor de serotonina 5-ht6 - Google Patents

Compuestos derivados de quinolina como moduladores del receptor de serotonina 5-ht6

Info

Publication number
PE20091187A1
PE20091187A1 PE2008001568A PE2008001568A PE20091187A1 PE 20091187 A1 PE20091187 A1 PE 20091187A1 PE 2008001568 A PE2008001568 A PE 2008001568A PE 2008001568 A PE2008001568 A PE 2008001568A PE 20091187 A1 PE20091187 A1 PE 20091187A1
Authority
PE
Peru
Prior art keywords
quinoline
alkyl
modulators
serotonin receptor
derived compounds
Prior art date
Application number
PE2008001568A
Other languages
English (en)
Inventor
Sean Colm Turner
Andreas Haupt
Wilfried Martin Braje
Udo Lange
Karla Drescher
Karsten Wicke
Liliane Unger
Mario Mezler
Wolfgang Wernet
Matthias Mayrer
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of PE20091187A1 publication Critical patent/PE20091187A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE QUINOLINA DE FORMULA (I), DONDE R ESTA DEFINIDO COMO (R); A ES CHR5 O CH2CHR5; R1, R2 Y R5 SON CADA UNO H ALQUILO(C1-C4), HALOALQUILO(C1-C4); ALCOXI(C1-C4) O HALOALCOXI(C1-C4); R3 ES H O ALQUILO(C1-C4); R4 ES H, ALQUILO(C1-C6), HIDROXIALQUILO(C1-C6), HALOALQUILO(C1-C6), ENTRE OTROS; n ES 0, 1 O 2; m ES 0, 1, 2 O 3; Ra Y Rb SON CADA UNO HALOGENO, CN, ALQUILO(C1-C4), ENTRE OTROS; X ES CH2, C(O), S, ENTRE OTROS; Ar ES Ar1, Ar2-Ar3 O Ar2-O-Ar3; DONDE Ar1, Ar2 Y Ar3 SON CADA UNO ARILO O HETEROARILO SUSTITUIDO OPCIONALMENTE POR 1, 2, 3 SUSTITUYENTES Rx; Rx ES HALOGENO, CN, NO2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CLORHIDRATO DE 8-(AZETIDIN-3-IL)-3-(FENILSULFONIL)QUINOLINA, CLORHIDRATO DE 3-(FENILSULFONIL)-8-PIPERIDIN-4-IL)QUINOLINA, 8-(1-BENCILPIRROLIDIN-3-IL)-3-(FENILSULFONIL)QUINILINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION PARA UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO TIENE ACTIVIDAD SOBRE EL RECEPTOR DE SEROTONINA 5-HT6, Y ES DE UTILIDAD EN EL TRATAMIENTO DE UNA ENFERMEDAD DEL SISTEMA NERVIOSO CENTRAL TAL COMO LA ENFERMEDAD DE ALZHEIMER
PE2008001568A 2007-03-23 2008-09-08 Compuestos derivados de quinolina como moduladores del receptor de serotonina 5-ht6 PE20091187A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104806 2007-03-23
PCT/EP2008/053387 WO2008116831A1 (en) 2007-03-23 2008-03-20 Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor

Publications (1)

Publication Number Publication Date
PE20091187A1 true PE20091187A1 (es) 2009-09-06

Family

ID=39620293

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001568A PE20091187A1 (es) 2007-03-23 2008-09-08 Compuestos derivados de quinolina como moduladores del receptor de serotonina 5-ht6

Country Status (24)

Country Link
US (1) US8242102B2 (es)
EP (1) EP2139880B1 (es)
JP (1) JP5538907B2 (es)
KR (1) KR20090128426A (es)
CN (1) CN101679351B (es)
AR (1) AR068381A1 (es)
AT (1) ATE524456T1 (es)
AU (1) AU2008231787A1 (es)
BR (1) BRPI0809081A2 (es)
CA (1) CA2681030C (es)
CO (1) CO6230989A2 (es)
CR (1) CR11039A (es)
DO (1) DOP2009000228A (es)
EC (1) ECSP099651A (es)
ES (1) ES2373617T3 (es)
IL (1) IL201105A0 (es)
MX (1) MX2009010243A (es)
NZ (1) NZ579735A (es)
PE (1) PE20091187A1 (es)
RU (1) RU2009139073A (es)
TW (1) TW200940524A (es)
UA (1) UA97837C2 (es)
UY (1) UY31326A (es)
WO (1) WO2008116831A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140120036A1 (en) * 2012-01-06 2014-05-01 Abbvie Inc. Radiolabeled 5-ht6 ligands
US20130343993A1 (en) * 2012-01-06 2013-12-26 Abbvie Inc. Radiolabeled 5-ht6 ligands
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
US10160744B2 (en) * 2016-03-14 2018-12-25 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
CN109503449A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6868700A (en) * 1999-09-02 2001-04-10 Wakunaga Pharmaceutical Co., Ltd Quinolinecarboxylic acid derivative or its salt
JP2003277416A (ja) * 2002-03-22 2003-10-02 Daiyanitorikkusu Kk 糖類を含むアクリルアミド水溶液
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
US20050165006A1 (en) 2002-04-03 2005-07-28 Dae-Yoon Chi Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
MXPA04012122A (es) 2002-06-05 2005-04-19 Hoffmann La Roche Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores del receptor 5-hidroxitriptamina 6 (5-5-ht6) para tratamiento de trastornos del sistema nervioso central (snc).
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
WO2007025798A2 (en) * 2005-07-27 2007-03-08 F. Hoffmann-La Roche Ag 4-aryloxy quinoline derivatives as 5-ht6 modulators
GB0519765D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
WO2008113818A1 (en) 2007-03-21 2008-09-25 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome

Also Published As

Publication number Publication date
DOP2009000228A (es) 2009-10-15
AR068381A1 (es) 2009-11-11
UY31326A (es) 2009-11-10
US8242102B2 (en) 2012-08-14
CN101679351A (zh) 2010-03-24
ATE524456T1 (de) 2011-09-15
UA97837C2 (ru) 2012-03-26
CA2681030C (en) 2015-01-13
US20110009380A1 (en) 2011-01-13
CR11039A (es) 2010-02-09
JP5538907B2 (ja) 2014-07-02
EP2139880B1 (en) 2011-09-14
CO6230989A2 (es) 2010-12-20
JP2010521520A (ja) 2010-06-24
NZ579735A (en) 2012-02-24
RU2009139073A (ru) 2011-04-27
TW200940524A (en) 2009-10-01
ECSP099651A (es) 2009-10-30
AU2008231787A1 (en) 2008-10-02
ES2373617T3 (es) 2012-02-07
MX2009010243A (es) 2009-12-14
CN101679351B (zh) 2015-01-07
KR20090128426A (ko) 2009-12-15
CA2681030A1 (en) 2008-10-02
EP2139880A1 (en) 2010-01-06
IL201105A0 (en) 2010-05-17
BRPI0809081A2 (pt) 2019-09-24
WO2008116831A1 (en) 2008-10-02
HK1139933A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
AR054799A1 (es) Derivados de oxindol
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR078786A1 (es) Derivados de la cromenona
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
UY28578A1 (es) Derivados de amida
PE20091100A1 (es) Nuevos compuestos 010
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR066583A1 (es) Derivados de 3,3-espiroindolinona
AR065863A1 (es) Derivados de imidazolidinona
PE20070181A1 (es) DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA
PE20091187A1 (es) Compuestos derivados de quinolina como moduladores del receptor de serotonina 5-ht6
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
AR067904A1 (es) Derivados de piperazina-amida

Legal Events

Date Code Title Description
FC Refusal